| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/24/2002 | US6455305 Nucleotide sequence of gene involved in cancer; anticarcinogenic agents |
| 09/24/2002 | US6455298 Animal cells and processes for the replication of influenza viruses |
| 09/24/2002 | US6455290 Tankyrase homolog protein (THP), nucleic acids, and methods related to the same |
| 09/24/2002 | US6455286 Psoralens for pathogen inactivation |
| 09/24/2002 | US6455278 Nucleic acid which encodes protein of defined amino acid sequence involved in pain perception; analgesics |
| 09/24/2002 | US6455277 Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides |
| 09/24/2002 | US6455080 Producing a chewing gum, as well as the chewing gum so produced, includes incorporating a modified release acyclic carboxamide into the gum composition. in one embodiment an acyclic carboxamide is made in a modified release structure |
| 09/24/2002 | US6455076 Formulations and methods for reducing skin irritation |
| 09/24/2002 | US6455072 Stable aqueous dispersion of nutrients |
| 09/24/2002 | US6455068 Chewable dietary fiber tablet or wager comprising, as a source of dietary fiber, a water-soluble, on-gelling inulin having a degree of polymerization of between 2 to 20, wherein the inulin is present in an amount of at least 50% by weight of |
| 09/24/2002 | US6455067 Alkyl-pyrrolidone 0.5-10 weight %, hydrophilic polyalkylene glycol 1-15 weight %, hydrophilic nonionic surfactant 0.01-3 weight %, water soluble polymer having carboxyl group 2-15 weight %, water soluble vinyl polymer 0.1-10 weight %, water |
| 09/24/2002 | US6455066 Intradermal-penetration agents for topical local anesthetic administration |
| 09/24/2002 | US6455062 An implantable device for providing systemic or local release of a therapeutic agent in tissue, the device comprising: therapeutic agent; an implant sized for insertion into tissue in which systemic or local release of the therapeutic agent |
| 09/24/2002 | US6455060 S(+) desmethylselegiline and its use to treat immune system dysfunction |
| 09/24/2002 | US6455054 Treating skin afflictions/conditions with 2-amino-4-alkylaminopyrimidine 3-oxide compounds |
| 09/24/2002 | US6455049 Biologically active and particularly peptide molecules having a potentiating effect on growth hormone biological activity |
| 09/24/2002 | US6455040 Sometimes referred to as ?tnfr-5? or ?tr5,? and now referred to hereinafter as ?trail receptor without intracellular domain? or ?trid.? |
| 09/24/2002 | US6455039 An isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with macrophase migration inhibiatory factor (mif) gene selected from dirofilaria immitis mif gene and onchocerca volvulus mif gene |
| 09/24/2002 | US6455032 Composition and method for protecting skin from UV induced immunosuppression and skin damage |
| 09/24/2002 | US6455028 Bronchodilator aerosol, propellant |
| 09/24/2002 | CA2404322A1 Medicament for the stimulation of leucopoiesis and treatment of tumour and protozoan diseases acarinosis and arthropod-borne diseases and a method for production thereof |
| 09/24/2002 | CA2261426C Benzimidazole cyclooxygenase-2-inhibitors |
| 09/24/2002 | CA2260914C Parasiticidal pyrazoles |
| 09/24/2002 | CA2257807C Improved methods for the synthesis of chemical compounds having pde-iv inhibitory activity |
| 09/24/2002 | CA2246584C Method of treating tourette's syndrome |
| 09/24/2002 | CA2220458C Form iii crystalline (r-(r*,r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
| 09/24/2002 | CA2220455C Novel process for the production of amorphous [r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| 09/24/2002 | CA2106683C Inactivating enveloped viruses and sperm |
| 09/24/2002 | CA2105487C Antiviral nucleoside combination |
| 09/24/2002 | CA2103223C Crystalline carbapenem derivative |
| 09/24/2002 | CA2096223C Treatment for tissue ulceration |
| 09/24/2002 | CA2076772C Novel vitamin d3 analogues |
| 09/24/2002 | CA2039477C Parenterally administrable liposome formulation comprising synthetic lipids |
| 09/23/2002 | CA2341952A1 Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases |
| 09/22/2002 | CA2378225A1 Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates |
| 09/20/2002 | WO2001070704A1 Novel imidazole derivatives with anti-inflammatory activity |
| 09/20/2002 | WO2001070692A2 Heterocyclic acylsulfimides, a method for their production, agents containing the same and their use as pesticides |
| 09/20/2002 | CA2403807A1 Heterocyclic acylsulfimides,processes for their preparation,compositionscomprising them and their use as pesticides |
| 09/20/2002 | CA2403732A1 Novel imidazole derivatives with anti-inflammatory activity |
| 09/20/2002 | CA2377453A1 Method of preventing retinopathy of prematurity in a neonate |
| 09/19/2002 | WO2002073235A2 Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
| 09/19/2002 | WO2002073208A2 Anti-epileptogenic agents |
| 09/19/2002 | WO2002073207A2 Isolated ductal fluid sample |
| 09/19/2002 | WO2002072809A1 Screening non-peptide, non-steroid invertebrate pheromone compounds for mitogen-activated protein kinase modulating activity |
| 09/19/2002 | WO2002072798A1 Fas ligand-expressing hematopoietic cells for transplantation |
| 09/19/2002 | WO2002072790A2 Tsg101-gag interaction and use thereof |
| 09/19/2002 | WO2002072776A2 Cell culture system for synthesis of infectious hepatitis c virus |
| 09/19/2002 | WO2002072616A2 Transfection complexes |
| 09/19/2002 | WO2002072599A1 Anti-apoptosis agents or regeneration promoters comprising ginsenosides |
| 09/19/2002 | WO2002072598A1 Steroids as agonists for fxr |
| 09/19/2002 | WO2002072596A1 Steap-related protein |
| 09/19/2002 | WO2002072587A1 Antidepressant azaheterocyclymethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline |
| 09/19/2002 | WO2002072585A2 Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics |
| 09/19/2002 | WO2002072584A2 Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders |
| 09/19/2002 | WO2002072581A2 Pyrazolopyriadine derivatives |
| 09/19/2002 | WO2002072579A1 Triazolopyridines as anti-inflammatory agents |
| 09/19/2002 | WO2002072577A2 Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors. |
| 09/19/2002 | WO2002072576A1 Benzimidazole anti-inflammatory compounds |
| 09/19/2002 | WO2002072574A1 Process for the preparation of imidazole compounds |
| 09/19/2002 | WO2002072573A1 Imidazolidine derivatives, their preparation, and their use as antinflamatory agent. |
| 09/19/2002 | WO2002072572A1 Quinolyl propyl piperidine derivatives, the preparation thereof and compositions containing same |
| 09/19/2002 | WO2002072570A2 Non-imidazole compounds as histamine h3 antagonists |
| 09/19/2002 | WO2002072569A1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same |
| 09/19/2002 | WO2002072564A1 N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same |
| 09/19/2002 | WO2002072559A1 Process to intermediates for biologically active compounds |
| 09/19/2002 | WO2002072558A1 Anti-thrombotic carboxylic acid amides, the production thereof and use of the same as medicaments |
| 09/19/2002 | WO2002072554A1 Anti-malarial compounds |
| 09/19/2002 | WO2002072550A1 Substituted dimethyl-[1-(1-phenyl-cyclohexyl)-piperidin-3-yl methyl]-amines and the use of the same as analgesics |
| 09/19/2002 | WO2002072548A2 Heterocyclic compounds and their use as histamine h4 ligands. |
| 09/19/2002 | WO2002072544A2 Multifluoro-substituted chalcones and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 09/19/2002 | WO2002072543A2 Rxr activating molecules |
| 09/19/2002 | WO2002072542A2 Ph-dependent nmda receptor antagonists |
| 09/19/2002 | WO2002072536A1 Urea derivatives having vanilloid receptor (vr1) antagonist activity |
| 09/19/2002 | WO2002072534A2 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof |
| 09/19/2002 | WO2002072532A1 7, 9-substituted tetracycline compounds |
| 09/19/2002 | WO2002072528A1 Fluorinated trienes and their use as rxr modulators |
| 09/19/2002 | WO2002072527A2 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 09/19/2002 | WO2002072448A1 Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein |
| 09/19/2002 | WO2002072202A1 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| 09/19/2002 | WO2002072151A1 Enzyme-activated cytostatic conjugates with integrin ligands |
| 09/19/2002 | WO2002072147A1 Medicinal compositions containing bile acid transporter inhibitor |
| 09/19/2002 | WO2002072146A2 Combination of nateglinide or repaglinide with at least one further antidiabetic compound |
| 09/19/2002 | WO2002072145A1 Remedies for depression containing ep1 antagonist as the active ingredient |
| 09/19/2002 | WO2002072143A1 Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives |
| 09/19/2002 | WO2002072137A2 Anaesthetic formulation comprising articaine |
| 09/19/2002 | WO2002072132A1 Combinations of heparin cofactor ii agonist and platelet iib/iiia antagonist, and uses thereof |
| 09/19/2002 | WO2002072127A2 Modulation of smooth muscle cell proliferation by vegf-x or antagonists thereof |
| 09/19/2002 | WO2002072120A1 Compositions comprising matrine and dictamnine for treating or preventing cancer and other diseases |
| 09/19/2002 | WO2002072114A2 Extracts of magnoliaceae plants and their use as anxiolytic and sedative agent |
| 09/19/2002 | WO2002072111A1 Telithromycin suspension with a masked taste |
| 09/19/2002 | WO2002072110A1 Caloporoside derivatives, methods for the production thereof and their use |
| 09/19/2002 | WO2002072108A1 Use of fluticasone propionate in the treatment of diseases ameliorated by enhancement of epithelial/matrix adhesion such as asthma, cystic fibrosis and influenza |
| 09/19/2002 | WO2002072107A1 Topical composition containing hydrocortisone |
| 09/19/2002 | WO2002072106A2 Combined method for treating hormono-dependent disorders with exemestane |
| 09/19/2002 | WO2002072105A2 Improved prostanoid therapies for the treatment of glaucoma |
| 09/19/2002 | WO2002072104A2 Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
| 09/19/2002 | WO2002072103A1 Use of type 4 phosphodiesterase inhibitors in myocardial diseases |
| 09/19/2002 | WO2002072102A1 Taste masked liquid pharmaceutical compositions |
| 09/19/2002 | WO2002072100A2 Pharmaceutical composition containing pde v inhibitors and surfactants |
| 09/19/2002 | WO2002072099A1 Therapeutic and/or preventive agent for diabetic ischemic heart disease |